Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Welichem Biotech, which develops therapeutic drugs in the fields of autoimmune diseases and cancer, has closed its non-brokered private placement announced on June 19, 2008.
Subscribe to our email newsletter
The company has raised gross proceeds of C$5 million through the issuance of 100 million units. Each unit consists of one common share and one-half of one share purchase warrant. Each whole share purchase warrant is exercisable into one common share at a price of C$0.10 for a period of 24 months from the date of issuance of the share purchase warrant.
All securities issued under the private placement will have a hold period expiring on October 21, 2008.
The proceeds from the financing will be used by the company to fund research, development and working capital.